127744-28-9

Usage

Uses

Used in Pharmaceutical Research:
(S)-3-BENZYLOXY-2-HYDROXY-PROPIONIC ACID METHYL ESTER is used as a key intermediate for the synthesis of pharmaceutical compounds, leveraging its chiral properties to create enantiomerically pure drugs with desired therapeutic effects.
Used in Organic Synthesis:
In the field of organic synthesis, (S)-3-BENZYLOXY-2-HYDROXY-PROPIONIC ACID METHYL ESTER is used as a building block for the preparation of various organic molecules, contributing to the development of new chemical entities with potential applications in different industries.
Used in the Production of Bioactive Compounds:
(S)-3-BENZYLOXY-2-HYDROXY-PROPIONIC ACID METHYL ESTER is utilized in the synthesis of bioactive compounds, which have potential applications in medicine, agriculture, and other fields, due to their ability to interact with biological systems and exhibit specific biological activities.
Used in Medicinal Chemistry:
(S)-3-BENZYLOXY-2-HYDROXY-PROPIONIC ACID METHYL ESTER is employed in medicinal chemistry for the development of new drugs and therapeutic agents, taking advantage of its chiral nature to design and optimize the pharmacological properties of drug candidates.
Used in Chemical Industry:
As an important intermediate in the chemical industry, (S)-3-BENZYLOXY-2-HYDROXY-PROPIONIC ACID METHYL ESTER is used in the production of a wide range of drugs and bioactive compounds, playing a vital role in the development and manufacturing processes of these products.

InChI:InChI=1/C11H14O4/c1-14-11(13)10(12)8-15-7-9-5-3-2-4-6-9/h2-6,10,12H,7-8H2,1H3/t10-/m0/s1

Upstream product

• 130111-08-9 (S)-3-(benzyloxy)-2-hydroxypropanoic acid 
• 149-73-5 trimethyl orthoformate 
• 23680-31-1 BOC-O-benzyl-L-serine 
• 67-56-1 methanol 
• 4726-96-9 O-Benzyl-L-serine 

Downstream Products

• 56552-80-8 (R)-3-benzyloxy-1,2-propanediol 
• 1060662-54-5 methyl (2R)-3-benzyloxy-2-[4'-(tert-butoxycarbonyl)-1'-piperazinyl]propanoate 
• 1403884-02-5 (R)-3-benzyloxy-2-(3-carbamoyl-2,4-difluoro-phenoxy)propionic acid methyl ester 
• 1403884-25-2 (R)-3-(2-(benzyloxy)-1-(6-chlorothiazolo[5,4-b]pyridin-2-yl)ethoxy)-2,6-difluorobenzonitrile 
• 1403884-22-9 (R)-3-(benzyloxy)-2-(3-carbamoyl-2,4-difluorophenoxy)propanoyl chloride 
• 1403884-23-0 (R)-3-(3-(benzyloxy)-1-(2,5-dichloropyridin-3-ylamino)-1-oxopropan-2-yloxy)-2,6-difluorobenzamide 
• 1403884-24-1 (R)-3-(benzyloxy)-2-(3-cyano-2,4-difluorophenoxy)-N-(2,5-dichloropyridin-3-yl)propanamide 
• 514829-77-7 3-benzyloxy-2-(S)-[4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl]-1-propanol 
• 16495-04-8 (S)-1-O-benzyl-3-p-toluenesulfonyl-syn-glycerol 
• 14618-80-5 (R)-benzyl glycidol 
• 127744-29-0 (S)-1-benzyloxy-3-(tert-butyldimethylsilanyloxy)propan-2-ol 

Relevant academic research and scientific papers

Total Synthesis of the Cyclic Depsipeptide Vioprolide D via its (Z)-Diastereoisomer

The first total synthesis of vioprolide D was accomplished in an overall yield of 2.0 % starting from methyl (2S)-3-benzyloxy-2-hydroxypropanoate (16 steps in the longest linear sequence). The cyclic depsipeptide was assembled from two building blocks of

MODULATORS OF THE INTEGRATED STRESS PATHWAY

Provided herein are compounds, compositions, and methods useful for the modulation of elF2B, for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

JAK1 SELECTIVE INHIBITORS

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.

MODULATORS OF THE INTEGRATED STRESS PATHWAY

Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.

POLYMYXIN ANALOGS USEFUL AS ANTIBIOTIC POTENTIATORS

The disclosure provides compounds of the formula (I) or a tautomer thereof, or a pharmaceutically acceptable salt of either of the foregoing. The variables A, R1, and R2 are defined in the disclosure. The disclosure further includes pharmaceutical compositions comprising a compound of formula I together with at least one pharmaceutically acceptable carrier. The disclosure also includes a method of sensitizing bacteria to an antibacterial agent, comprising administering to a patient infected with the bacteria, simultaneously or sequentially, a therapeutically effective amount of the antibacterial agent and a compound of formula (I).

Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ

The design, synthesis and structure-activity relationships of a series of oxazole-benzamide inhibitors of the essential bacterial cell division protein FtsZ are described. Compounds had potent anti-staphylococcal activity and inhibited the cytokinesis of the clinically-significant bacterial pathogen Staphylococcus aureus. Selected analogues possessing a 5-halo oxazole also inhibited a strain of S. aureus harbouring the glycine-to-alanine amino acid substitution at residue 196 of FtsZ which conferred resistance to previously reported inhibitors in the series. Substitutions to the pseudo-benzylic carbon of the scaffold improved the pharmacokinetic properties by increasing metabolic stability and provided a mechanism for creating pro-drugs. Combining multiple substitutions based on the findings reported in this study has provided small-molecule inhibitors of FtsZ with enhanced in vitro and in vivo antibacterial efficacy.

Design, synthesis and structure-activity relationships of substituted oxazole-benzamide antibacterial inhibitors of FtsZ

The design, synthesis and structure-activity relationships of a series of oxazole-benzamide inhibitors of the essential bacterial cell division protein FtsZ are described. Compounds had potent anti-staphylococcal activity and inhibited the cytokinesis of the clinically-significant bacterial pathogen Staphylococcus aureus. Selected analogues possessing a 5-halo oxazole also inhibited a strain of S. aureus harbouring the glycine-to-alanine amino acid substitution at residue 196 of FtsZ which conferred resistance to previously reported inhibitors in the series. Substitutions to the pseudo-benzylic carbon of the scaffold improved the pharmacokinetic properties by increasing metabolic stability and provided a mechanism for creating pro-drugs. Combining multiple substitutions based on the findings reported in this study has provided small-molecule inhibitors of FtsZ with enhanced in vitro and in vivo antibacterial efficacy.

AROMATIC AMIDES AND USES THEREOF

The present invention provides compounds of Formula (I): and salts, racemates, isomers, diastereoisomers, enantiomers, hydrates, solvates, N-oxides, pharmaceutically acceptable derivatives or prodrugs thereof. Also provided the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture.

New efficient enantioselective synthesis of 2-oxopiperazines: a practical access to chiral 3-substituted 2-oxopiperazines

The development of efficient and stereoselective methods to produce 1,4-disubstituted-2-oxopiperazine in enantiomerically pure form, from a readily available starting material is crucial. Herein, we report a reduction modification to our previously descri

Process improvements for the preparation of kilo quantities of a series of isoindoline compounds

A series of isoindoline analogues with either an indazole (HMR 2934, HMR 2651) or benzisoxazole (HMR 2543) appendage were prepared for the proposed treatment of psychiatric disorders such as obsessive compulsive disorder and attention deficit disorder. The isoindoline compounds were prepared by reduction of the corresponding phthalimides with LiAlH4. One compound was not chiral, and the other two required an enantioselective synthesis. The key step for these optically active analogues involved the coupling by an SN2 process of either a piperazynyl intermediate or a piperdinyl intermediate with methyl 3-benzyloxy-2-trifluoromethansulfonatopropionate. The products for these two analogues had >98% ee. Process improvements led to the multi-kilogram syntheses of each of these compounds.